No Data
No Data
Analysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH) and Ocugen (OCGN)
Noble Financial Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $8
Express News | Ocugen Has Completed Dosing In Third Cohort Of Phase 1/2 ArMaDa Trial For OCU410 (AAV-hRORA) For Geographic Atrophy, The Company Has Initiated Phase 2 Trial To Assess OCU410 In Larger Group Of Patients
Express News | Ocugen, Inc. Announces Completion of Dosing in Subjects With Geographic Atrophy Secondary to Damd in High-Dose Cohort of Phase 1/2 Armada Clinical Trial of Ocu410—a Novel Modifier Gene Therapy
Ocugen, Inc. Announces Completion of Dosing in Subjects With Geographic Atrophy Secondary to DAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
Trending Stocks Today: NANO Nuclear Energy Inches up 8.83% Post-Market
No Data